v3.25.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION
13. SEGMENT INFORMATION
We operate in a single segment dedicated to the discovery, development, manufacturing and commercialization of RNAi therapeutics. Consistent with our management reporting, results of our operations are reported on a consolidated basis for purposes of segment reporting. Our Chief Executive Officer, or CEO, as the chief operating decision maker, or CODM, evaluates performance and decides how to allocate resources based on consolidated net income (loss) that is reported on the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets. Please refer to the condensed consolidated financial statements for further information related to these measures of segment performance. In addition, research and development and selling, general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories:
Research and Development
Three Months Ended
March 31,
(In thousands)
20252024
Clinical research and outside services$127,343 $125,510 
Compensation and related99,187 96,424 
Occupancy and all other costs(1)
38,592 39,061 
Total research and development expense
$265,122 $260,995 
Selling, General and Administrative
Three Months Ended
March 31,
(In thousands)
20252024
Compensation and related
$131,437 $117,341 
Consulting and professional services
64,687 56,759 
Occupancy and all other costs(1)
43,825 36,697 
Total selling, general and administrative expense
$239,949 $210,797 
(1) Occupancy and all other costs includes facilities, information technology, depreciation and certain departmental expenses.